Matthew Seymour, MD: A Clinical Trialist’s Perspective

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Nov

Today In Oncology

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Related Videos

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Pancreatic Cancer Mild Duct Dilation May Serve as Early Indicator in High-Risk Patients

Preliminary Activity of LuPSMA-IT Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis

Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer

SABR May Be Comparable to Surgery for Early-Stage NSCLC

MD Anderson Launches 2.5 Billion Philanthropic Campaign